Investment Rating - The report maintains a "Buy" rating for Qianhong Pharmaceutical (002550) [1] Core Views - The company is successfully transitioning towards innovation, with a significant improvement in the gross margin of its formulation business and signs of recovery in its raw material drug segment [8] - The company has achieved revenue of 862 million yuan in H1 2025, representing a year-on-year increase of 0.72%, and a net profit attributable to shareholders of 258 million yuan, up 41.17% year-on-year [8] - The company has four innovative drug pipelines in Phase II clinical trials or about to enter Phase III, indicating a fruitful period for its long-term investment in innovation [8] Financial Performance - Revenue forecast for 2025-2027 is 20.51 billion yuan, 27.37 billion yuan, and 32.83 billion yuan respectively, with net profits of 4.43 billion yuan, 5.12 billion yuan, and 6.09 billion yuan [1][9] - The gross margin for the formulation business increased significantly to 69.90% in H1 2025, up 8.54 percentage points year-on-year, primarily due to a substantial decrease in costs [8] - The raw material drug business saw a revenue increase of 17.52% in H1 2025, marking the first revenue growth after eight consecutive quarters of decline [8] Market Data - The closing price of the stock is 10.90 yuan, with a market capitalization of approximately 13.95 billion yuan [5] - The price-to-earnings ratio (P/E) is projected to be 31.48 for 2025, decreasing to 22.91 by 2027 [1][9]

千红制药 20250801 摘要 2019-2022 年千红制药受益于甘肃价格上涨，主要因非洲猪瘟及疫情 期间下游囤货需求旺盛。但 2023 年二季度至 2024 年二季度，甘肃价 格从 5 万元/亿单位跌至 2 万元/亿单位，严重影响业绩。 千红制药创新药管线进入收获期，106（治疗急性缺血性脑卒中）和 107（治疗难治复发急性髓系白血病）备受关注。106 预计销售峰值 40 亿元，2024 年 9 月启动三期临床，预计 2027 年初申报上市；107 是 疗效最优且研发进度最快的 CDK9 抑制剂。 千红制药主业为肝素原料药和制剂，甘肃市场增速放缓，供需平衡导致 价格处于历史底部。甘肃粗品价格随甘肃价格下滑，企业库存及周转率 影响利润率修复。公司低库存政策提升利润率。 公司曾因信托爆雷计提减值，2024 年起逐步收回信托款项并冲回，预 计 2025 年继续冲回，修复表观利润。2018-2023 年平均现金分红 1.35 亿元，平均股息率超 3%，分红政策稳定。 千红制药毛利率修复快于竞争对手，归因于低库存政策。高库存企业在 甘肃价格下行时受损，千红制药受益于低价原料。预计 2025 年半年报 毛利率达 6 ...